Gilead's Earnings Take a Dive as AIDS Drug Sales Soften
By Catherine Shaffer
Friday, April 22, 2011
Weak sales of its HIV drugs in the U.S. pushed Gilead Sciences Inc.'s earnings down in the first quarter. Revenues of $1.93 billion were below consensus estimates and down 8 percent from the first quarter of 2010.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.